OncLive.com
@onclive
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
ID: 43051682
http://www.onclive.com 28-05-2009 05:04:27
110,110K Tweet
46,46K Takipçi
1,1K Takip Edilen
Single-agent IBI322 elicited responses with favorable safety in patients with classical HL that had become resistant to anti–PD-1/PD-L1 therapy, according to data from a phase 1 trial. European Hematology Association #EHA2023 #EHA23 #lymsm ow.ly/WCl750PAweP